A Novel Tumor Suppressor SPINK5 Serves as an Independent Prognostic Predictor for Patients with Head and Neck Squamous Cell Carcinoma

In our previous study, serine protease inhibitor Kazal-type 5 (SPINK5), which encodes the product of serine protease inhibitor lymphoepithelial Kazal-type-related inhibitor (LEKTI) was found to be down-regulated in head and neck squamous cell carcinoma (HNSCC) using oligonucleotide microarrays. Howe...

Full description

Saved in:
Bibliographic Details
Published in:Cancer management and research 2020-01, Vol.12, p.4855-4869
Main Authors: Lv, Zhongjing, Wu, Kun, Qin, Xing, Yuan, Jian, Yan, Ming, Zhang, Jianjun, Wang, Lizhen, Ji, Tong, Cao, Wei, Chen, Wantao
Format: Article
Language:English
Subjects:
biological function
Care and treatment
head and neck squamous cell carcinoma
Immunohistochemistry
Medical schools
Original Research
prognostic predictor
Protease inhibitors
spink5/lekti
Squamous cell carcinoma
Thrombin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In our previous study, serine protease inhibitor Kazal-type 5 (SPINK5), which encodes the product of serine protease inhibitor lymphoepithelial Kazal-type-related inhibitor (LEKTI) was found to be down-regulated in head and neck squamous cell carcinoma (HNSCC) using oligonucleotide microarrays. However, the function and clinical implications of SPINK5/LEKTI remain obscure in HNSCC. The endogenous expression level of SPINK5/LEKTI was further verified in 9 HNSCC cell lines and HNSCCs by means of reverse transcription-polymerase chain reaction, real-time PCR, Western blotting and immunohistochemistry. The biological function of SPINK5/LEKTI was investigated in vitro and in vivo experiments. Kaplan-Meier survival analysis and Cox proportional hazards regression model were used to determine the correlation between SPINK5/LEKTI expression and clinical outcome. Down-regulation expression of SPINK5/LEKTI was found in six out of nine HNSCC cell lines and in 85.7% HNSCC specimens (
ISSN:1179-1322
1179-1322
DOI:10.2147/CMAR.S236266